U.S. GLP-1 Receptor Agonists Market (2026-2036)

The U.S. GLP-1 Receptor Agonists Market comprises prescription medicines that activate the glucagon-like peptide-1 receptor, alone or in combination with other incretin receptors, to lower blood glucose, reduce appetite, and promote weight loss, sold in the United States. The market covers tirzepatide, a dual GIP and GLP-1 receptor agonist marketed as Mounjaro for type 2 diabetes and Zepbound for obesity; semaglutide, marketed as Ozempic and oral Rybelsus for type 2 diabetes and Wegovy for obesity; dulaglutide, marketed as Trulicity; liraglutide, marketed as Victoza and Saxenda; and next-generation incretins, including oral small-molecule GLP-1 agonists such as orforglipron and multi-agonists such as retatrutide. Indications include type 2 diabetes, obesity and chronic weight management, cardiovascular risk reduction, obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis, and chronic kidney disease. Market value is measured at manufacturer net sales; compounded and unapproved products are excluded. The ecosystem spans pharmaceutical manufacturers, contract manufacturers, pharmacy benefit managers, insurers, employers, Medicare and Medicaid, pharmacies, telehealth companies, physicians, and patients.

Novo Nordisk, the pioneer of semaglutide, faces rising competition and guided to a 5% to 13% sales decline for 2026.

Access and pricing are changing rapidly. In November 2025, the White House announced agreements with Eli Lilly and Novo Nordisk under which Medicare Part D coverage for obesity medicines would be available through a pilot beginning 1 April 2026, with copays of no more than USD 50 per month, and new formulations would be offered at lower prices. Lilly has expanded direct-to-patient sales of Zepbound vials, which represented about one-third of total Zepbound prescriptions and nearly half of new Zepbound prescriptions in the fourth quarter of 2025, and guided that realized prices would decline by low to mid teens in 2026. The U.S. Food and Drug Administration declared the national shortages of tirzepatide and semaglutide resolved in late 2024 and early 2025, respectively, limiting mass compounding.

The clinical foundation is strong. The Centers for Disease Control and Prevention reported adult obesity prevalence of about 40% in 2021 to 2023, and about 38 million Americans have diabetes. Semaglutide and tirzepatide have gained approvals beyond diabetes and weight management, including cardiovascular risk reduction, obstructive sleep apnea, MASH, and chronic kidney disease, and oral options are arriving, with an oral form of Wegovy approved in December 2025 and Lilly having submitted orforglipron, with approval expected in the second quarter of 2026. At the same time, declining prices, coverage gaps, discontinuation, compounded products, and budget pressures present challenges.

In 2026, the South is expected to account for the largest share of the U.S. GLP-1 Receptor Agonists Market. The region's dominance is supported by its large population and high prevalence of obesity and diabetes. The South includes many of the states with the highest adult obesity rates, according to the Centers for Disease Control and Prevention, which reported that 23 states had adult obesity prevalence of 35% or higher in 2023, and includes the so-called diabetes belt of high type 2 diabetes prevalence. Large populous states such as Texas and Florida account for substantial prescription volumes, although some public employer plans in the region, such as North Carolina's State Health Plan in 2024, have restricted obesity drug coverage.

However, the Midwest is projected to register the highest CAGR during the forecast period. The rapid growth of the region is attributed to high adult obesity prevalence, with many Midwestern states among the 23 states reported by the CDC as having obesity prevalence of 35% or higher in 2023, an older population that will benefit from Medicare Part D obesity coverage beginning 1 April 2026, and expanding access through direct-to-patient channels in areas with fewer specialists. Indianapolis-based Eli Lilly, whose U.S. diabetes and obesity revenue rose 54% in the fourth quarter of 2025, is headquartered in the region and is expanding U.S. manufacturing.

The West is expected to account for a significant share of the market. The region has generally lower adult obesity prevalence than the South and Midwest but a large population, led by California, and high adoption of telehealth and direct-to-patient channels, through which Zepbound vials accounted for nearly half of new Zepbound prescriptions nationally in the fourth quarter of 2025. California's Medi-Cal program ended coverage of GLP-1 drugs for weight loss in 2026 because of cost, illustrating budget pressures, while commercial insurance and cash-pay channels support demand. Western states generally fall outside the 23 states that the CDC reported as having adult obesity prevalence of 35% or higher in 2023, but the region's large insured population and early adoption of oral therapies, including oral Wegovy approved in December 2025, support steady growth.

The Northeast is expected to account for a moderate share of the market. The region has relatively lower adult obesity prevalence but high health insurance coverage rates, dense networks of academic medical centers and obesity medicine specialists, and generally broader commercial and Medicaid coverage for chronic disease treatments. New Jersey hosts U.S. operations of Novo Nordisk, and the region's older population will benefit from Medicare Part D obesity coverage beginning in April 2026 with copays capped at USD 50 per month. Medicare negotiated prices for semaglutide, scheduled to take effect in 2027 under the Inflation Reduction Act, are expected to improve affordability for the region's large Medicare population, while dense specialist networks support uptake of new indications such as cardiovascular risk reduction and MASH.